Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aileron Overcoming Spirited Debate About Stapled Peptides

This article was originally published in The Pink Sheet Daily

Executive Summary

The new, promising class of drugs is rolling toward the clinic, but a respected research group recently thrust a stick in the spokes and prompted a call for wider access to the technology.

You may also be interested in...



Aileron Raises $30M From Existing Investors To Advance Pair Of Stapled Peptide Candidates

The Cambridge, Mass., biotech plans to bring a candidate for cancer into clinical development next year, while starting Phase Ib dose-finding research with its endocrinology disorder candidate.

Heptares And Complix Raise Series B Funds To Advance Preclinical Compounds

GPCR-focused Heptares and the protein scaffold company Complix complete a seemingly rare event for European biotechs, a second round of VC funding.

Pharma Deals That Generate Lasting Value: A Roundtable Discussion

At Elsevier Business Intelligence's recent Therapeutic Area Partnerships conference, a  roundtable of senior pharmaceutical executives and entrepreneurs weighed in on industry’s current funding challenges, how dealmaking defines a biotech’s ambitions and strategy, and pharma’s appetite for early-stage innovation.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel